Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis
Status:
Completed
Trial end date:
2018-01-22
Target enrollment:
Participant gender:
Summary
Sporadic Inclusion Body Myositis (IBM) is the most frequent inflammatory myopathy in patients
over 50. It is a slowly progressive, but today untreatable (notably by classical
immunosuppressants) disease.
Rapamycin used in organ transplantation blocks the activity of T effector cells, preserves T
regulatory cells and induces autophagy (protein degradation), all parameters impaired during
IBM.
RAPAMI is a prospective, randomised, controlled, double blind, monocentric, phase IIb trial
evaluating rapamycine against placebo.